Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-213399
Filing Date
2026-05-08
Accepted
2026-05-08 08:11:39
Documents
75
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alxo-20260331.htm   iXBRL 10-Q 2621571
2 EX-10.1 alxo-ex10_1.htm EX-10.1 58656
3 EX-31.1 alxo-ex31_1.htm EX-31.1 19638
4 EX-31.2 alxo-ex31_2.htm EX-31.2 19870
5 EX-32.1 alxo-ex32_1.htm EX-32.1 11685
6 EX-32.2 alxo-ex32_2.htm EX-32.2 11709
  Complete submission text file 0001193125-26-213399.txt   9871031

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alxo-20260331.xsd EX-101.SCH 1172535
79 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20260331_htm.xml XML 1774125
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39386 | Film No.: 26956167
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)